沙美特罗氟替卡松联合孟鲁司特钠治疗难治性哮喘患者的临床研究

Salmeterol Fluticasone Combined with Montelukast Sodium in the Treatment of Patients with Refractory Asthma

目的探讨难治性哮喘患者应用沙美特罗氟替卡松联合孟鲁司特钠治疗的临床疗效。方法随机选取2017年9月—2019年12月难治性哮喘患者50例为研究对象,以随机信封法,分为病例组和对照组,每组25例,两组患者均给予常规治疗的同时,对照组应用沙美特罗氟替卡松吸入治疗,病例组患者在对照组的基础上联合孟鲁司特钠口服治疗,比较两组患者治疗前后肺功能水平、临床缓解情况。结果治疗前,病例组第1秒用力呼气容积(FEV1)占用力肺活量(FVC)的百分比为(53.17±3.56)%,第1秒用力呼气容积占预计值的百分比(FEV1%)为(63.69±3.43)%,对照组为(55.29±2.64)%、(64.24±3.57)%,组间差异无统计学意义(t=2.392、0.555,P>0.05);治疗后病例组FEV1/FVC为(80.40±3.70)%,FEV1%为(74.88±3.53)%,优于对照组(64.16±2.79)%、(69.12±4.88)%,差异有统计学意义(t=17.520、4.782,P<0.05);治疗前,病例组FEV1为(1.73±0.59)L、呼气峰值流速(PEF)为(2.13±0.53)L/s,对照组为(1.69±0.51)L、(2.21±0.45)L/s,差异无统计学意义(t=0.256、0.575,P>0.05);治疗后,病例组FEV1为(2.31±0.47)L、PEF为(2.69±0.41)L/s,均高于对照组,差异有统计学意义(t=2.209、2.114,P<0.05)。结论吸入性沙丁胺醇氟替卡松联合口服孟鲁司特钠片可以使得难治性哮喘患者肺部炎症状况好转,缓解临床症状,临床疗效可。

Objective To investigate the clinical efficacy of salmeterol fluticasone combined with montelukast in patients with refractory asthma.Methods Randomly select 50 patients with refractory asthma from September 2017 to December 2019 as the research objects.Using the random envelope method,they were divided into a case group and a control group with 25 cases in each group.Both groups were given conventional treatment at the same time as the control group.Salmeterol fluticasone inhalation treatment was used in the control group,and the patients in the case group were treated with montelukast sodium orally on the basis of the control group.The lung function level and clinical remission of the two groups were compared before and after treatment.Results Before treatment,the percentage of forced expiratory volume(FEV1)in the first second in the case group was(53.17±3.56)%,The forced expiratory volume in the first second as a percentage of the predicted value(FEV1%)was(63.69±3.43)%,and the control group was(55.29±2.64)%,(64.24±3.57)%,the difference between groups was not statistically significant(t=2.392,0.555,P>0.05);FEV1/FVC in the case group after treatment was(80.40±3.70)%,FEV1%was(74.88±3.53)%,Better than the control group(64.16±2.79)%,(69.12±4.88)%,the difference was statistically significant(t=17.520,4.782,P<0.05);before treatment,the FEV1 of the case group was(1.73±0.59)L,Peak expiratory flow rate(PEF)was(2.13±0.53)L/s,and the control group was(1.69±0.51)L,(2.21±0.45)L/s,the difference was not statistically significant(t=0.256,0.575,P>0.05);After treatment,the FEV1 of the case group was(2.31±0.47)L and the PEF was(2.69±0.41)L/s,which were higher than those of the control group,and the difference was statistically significant(t=2.209,2.114,P<0.05).Conclusion Inhaled salbutamol and fluticasone combined with oral montelukast sodium tablets can improve the pulmonary inflammation in patients with refractory asthma.It relieves clinical symptoms,has good clinical effects.